Author Topic: Long-term treatment w/anti-CD20 monoclonal antibodies untenable because of risk?  (Read 219 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest

Multiple Sclerosis Journal routinely publishes a "Controversies in MS" section, where one side of a controversial topic is presented, followed by the opposing view, and concluding with a comment on both presentations. This time there is only the "Yes" side of the controversy, in an article entitled "Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: YES" (April 18, 2022). This is a PDF file:


https://bit.ly/3vBeriH


The drugs that are anti-CD20 monoclonal antibodies are ocrelizumab (Ocrevus),  ofatumumab (Kesimpta),  and the off-label-use drug rituximab (Rituxan)
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
The latest issue of Multiple Sclerosis Journal (June 9, 2022)has reprinted the article cited above as well as the "No" side of the debate, and both are summarized in the attached "Commentary":


https://journals.sagepub.com/doi/full/10.1177/13524585221101138
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
56 Views
Last post October 27, 2019, 09:47:35 pm
by agate
0 Replies
37 Views
Last post May 09, 2021, 09:37:37 pm
by agate
0 Replies
18 Views
Last post November 23, 2021, 09:01:13 pm
by agate
0 Replies
22 Views
Last post February 22, 2023, 09:25:13 pm
by agate
0 Replies
17 Views
Last post June 23, 2023, 03:26:55 pm
by agate